Therapeutic failure reported with <scp>HIV</scp> long‐acting injectables: An analysis of the <scp>FDA</scp> Adverse Event Reporting System from 2021 to 2024
Our findings suggest that healthcare professionals should have a heightened awareness of potential challenges with CAB/RPV administration, including TFs and dose omissions in real-world settings.
Authors
- Danielle L. Cabral (ORCID: https://orcid.org/0000-0001-7821-8550)
- Kenneth L. McCall (ORCID: https://orcid.org/0000-0003-2061-108X)
- Ashante M. Concepcion
- Kristine E. Denimarck
- Shawn S. Shalumov
- J. Coghlan
Institutions
- Binghamton University (US)
- Northwell Health (US)
Publication Details
- Journal
- HIV Medicine
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1111/hiv.13709
- Citations
- 5
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 5.55